Cargando…

Downregulation of miR-194-5p induces paclitaxel resistance in ovarian cancer cells by altering MDM2 expression

Paclitaxel is a first-line drug for treating epithelial ovarian cancer (EOC). However, prognosis for patients with advanced stage cancer remains poor due to primary or acquired drug resistance. Therefore, overcoming chemoresistance is one of the greatest challenges in treating EOC. In this study, we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nakamura, Koji, Sawada, Kenjiro, Miyamoto, Mayuko, Kinose, Yasuto, Yoshimura, Akihiko, Ishida, Kyoso, Kobayashi, Masaki, Shimizu, Aasa, Nakatsuka, Erika, Hashimoto, Kae, Mabuchi, Seiji, Kimura, Tadashi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2019
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6363016/ https://www.ncbi.nlm.nih.gov/pubmed/30774764 http://dx.doi.org/10.18632/oncotarget.26586

Ejemplares similares

Paclitaxel exposure downregulates miR-522 expression and its downregulation induces paclitaxel resistance in ovarian cancer cells
por: Miyamoto, Mayuko, et al.
Publicado: (2020)

Exosomal miR-99a-5p is elevated in sera of ovarian cancer patients and promotes cancer cell invasion by increasing fibronectin and vitronectin expression in neighboring peritoneal mesothelial cells
por: Yoshimura, Akihiko, et al.
Publicado: (2018)

Exosomal miR-1290 is a potential biomarker of high-grade serous ovarian carcinoma and can discriminate patients from those with malignancies of other histological types
por: Kobayashi, Masaki, et al.
Publicado: (2018)

Effects of minodronate in postmenopausal women with osteoporosis who received prior treatment with raloxifene
por: Toda, Aska, et al.
Publicado: (2017)

Clinical effects of switching from minodronate to denosumab treatment in patients with postmenopausal osteoporosis: a retrospective study
por: Kobayashi, Masaki, et al.
Publicado: (2020)

Clinical relevance of circulating cell-free microRNAs in ovarian cancer
por: Nakamura, Koji, et al.
Publicado: (2016)

The hypoxia-related microRNA miR-199a-3p displays tumor suppressor functions in ovarian carcinoma
por: Kinose, Yasuto, et al.
Publicado: (2015)

Role of the Exosome in Ovarian Cancer Progression and Its Potential as a Therapeutic Target
por: Nakamura, Koji, et al.
Publicado: (2019)

Safety and efficacy of Ninjin’yoeito along with iron supplementation therapy for preoperative anemia, fatigue, and anxiety in patients with gynecological disease: an open-label, single-center, randomized phase-II trial
por: Yagi, Taro, et al.
Publicado: (2022)

Clinical trial assessing the safety of edoxaban with concomitant chemotherapy in patients with gynecological cancer-associated thrombosis (EGCAT study)
por: Oride, Tadashi, et al.
Publicado: (2023)

Plasminogen activator inhibitor-1 is an independent prognostic factor of ovarian cancer and IMD-4482, a novel plasminogen activator inhibitor-1 inhibitor, inhibits ovarian cancer peritoneal dissemination
por: Nakatsuka, Erika, et al.
Publicado: (2017)

Effect of Japanese Kampo Medicine Therapy for Menopausal Symptoms after Treatment of Gynecological Malignancy
por: Yoshimura, Akihiko, et al.
Publicado: (2018)

Interleukin 6 Receptor Is an Independent Prognostic Factor and a Potential Therapeutic Target of Ovarian Cancer
por: Isobe, Aki, et al.
Publicado: (2015)

The Role of MicroRNAs in Ovarian Cancer
por: Kinose, Yasuto, et al.
Publicado: (2014)

Identification of Malignant Cell Populations Associated with Poor Prognosis in High-Grade Serous Ovarian Cancer Using Single-Cell RNA Sequencing
por: Sumitani, Naoki, et al.
Publicado: (2022)

Laparoscopic spacer placement for bulky lymph node metastasis of cervical cancer: A case report
por: Kuruma, Airi, et al.
Publicado: (2022)

Preclinical Investigations of PM01183 (Lurbinectedin) as a Single Agent or in Combination with Other Anticancer Agents for Clear Cell Carcinoma of the Ovary
por: Takahashi, Ryoko, et al.
Publicado: (2016)

Gastric-Type Adenocarcinoma of the Uterine Cervix Associated with Poor Response to Definitive Radiotherapy
por: Kuruma, Airi, et al.
Publicado: (2022)

Pathophysiological Role and Potential Therapeutic Exploitation of Exosomes in Ovarian Cancer
por: Shimizu, Aasa, et al.
Publicado: (2020)

A single institution’s experience with minimally invasive surgery for ovarian cancer, and a systematic meta-analysis of the literature
por: Kamei, Yuji, et al.
Publicado: (2023)

Prognostic significance of bone marrow FDG uptake in patients with gynecological cancer
por: Shimura, Kotaro, et al.
Publicado: (2021)

The significance of G-CSF expression and myeloid-derived suppressor cells in the chemoresistance of uterine cervical cancer
por: Kawano, Mahiru, et al.
Publicado: (2015)

Prostaglandin E2 produced by myeloid-derived suppressive cells induces cancer stem cells in uterine cervical cancer
por: Kuroda, Hiromasa, et al.
Publicado: (2018)

Estrogen stimulates female cancer progression by inducing myeloid-derived suppressive cells: investigations on pregnant and non-pregnant experimental models
por: Kozasa, Katsumi, et al.
Publicado: (2019)

Benzimidazoles Downregulate Mdm2 and MdmX and Activate p53 in MdmX Overexpressing Tumor Cells
por: Mrkvová, Zuzana, et al.
Publicado: (2019)

Chemoradiotherapy followed by consolidation chemotherapy involving paclitaxel and carboplatin and in FIGO stage IIIB/IVA cervical cancer patients
por: Mabuchi, Seiji, et al.
Publicado: (2017)

Intensity-modulated radiation therapy versus three-dimensional conformal radiation therapy with concurrent nedaplatin-based chemotherapy after radical hysterectomy for uterine cervical cancer: comparison of outcomes, complications, and dose-volume histogram parameters
por: Isohashi, Fumiaki, et al.
Publicado: (2015)

Stinging abdominal pain at 32 gestational weeks with prior classical uterine incision: Careful assessment or emergency cesarean delivery?
por: Kakigano, Aiko, et al.
Publicado: (2021)

Future plans of PS 194
por: Knudsen, H, et al.
Publicado: (1995)

Health Tract, No. 194: Memories
Publicado: (1865)

Subject Index to Volume 194
Publicado: (2006)

Direct mass measurements of $^{194}$Hg and $^{194}$Au : A new route to the neutrino mass determination?
por: Eliseev, S, et al.
Publicado: (2010)

Nedaplatin: A Radiosensitizing Agent for Patients with Cervical Cancer
por: Mabuchi, Seiji, et al.
Publicado: (2011)

On future activities of the PS194 Collaboration
por: Uggerhøj, Erik
Publicado: (1990)

LncRNA NEAT1 contributes to paclitaxel resistance of ovarian cancer cells by regulating ZEB1 expression via miR-194
por: An, Jihong, et al.
Publicado: (2017)

Utility of serum squamous cell carcinoma antigen levels at the time of recurrent cervical cancer diagnosis in determining the optimal treatment choice
por: Shimura, Kotaro, et al.
Publicado: (2013)

miR-194 Inhibits the Proliferation of SW620 Colon Cancer Stem Cells Through Downregulation of SSH2 Expression
por: Sun, Bo, et al.
Publicado: (2019)

Etude de la désintégration $^{194}$Au --> $^{194}$Pt (T$_{1/2}$ = 53.0 $^{\pm}$ 1.4 s)
por: Caillau, M, et al.
Publicado: (1974)

194th W.E. Heraeus Seminar
por: Clark, John W, et al.
Publicado: (1999)

New features of superdeformed bands in $^{194}$Hg
por: Cederwall, Bo, et al.
Publicado: (1994)

Cannot write session to /tmp/vufind_sessions/sess_20lotfle9k0iob07nktn7pvg1t